Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Nova Scotia still hasn’t signed on to the federal government’s pharmacare plan, and the province’s Opposition New Democrats are wondering why.

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 EPS, expectations were $-0.26681. Operator: Hello, and welcome to the ...

Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(10):1085-1102. doi:org/10.1002/ajh.24876 National Library of Medicine.

This asset is under development for the treatment of cutaneous T cell lymphoma, an indication ... the Phase 2 in CTCL in Sezary syndrome and mycosis fungoides were presented at ASH 2023 and ...

The Johns Hopkins T-cell and Cutaneous Lymphoma Program provides expertise in all forms of systemic peripheral T-cell lymphomas and cutaneous T-cell lymphomas, including mycosis fungoides and others.

The research groups led by Wolfgang Kastenmüller and Georg Gasteiger employed innovative microscopy techniques to observe how ...